Defining consensus leukemia-associated immunophenotypes for detection of minimal residual disease in acute myeloid leukemia in a multicenter setting

Blood Cancer Journal

Volumn 3, Issue 8, 2013, Pages

  Feller, N ^a   Van Der Velden, V H J ^b   Brooimans, R A ^b   Boeckx, N ^c,d   Preijers, F ^e   Kelder, A ^a   De Greef, I ^b   Westra, G ^a   Te Marvelde, J G ^b   Aerts, P ^b   Wind, H ^b   Leenders, M ^e   Gratama, J W ^b   Schuurhuis, G J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d UNIVERSITY OF LEUVEN   (Belgium)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Flow cytometry; Minimal residual disease; Multicenter

Indexed keywords

MOLECULAR MARKER;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CHILD; CLINICAL TRIAL; COMPARATIVE STUDY; CONSENSUS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE COURSE; EVALUATION; EXPERIENCE; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; LEUKEMIA ASSOCIATED IMMUNOPHENOTYPE; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; MULTICENTER STUDY; PRACTICE GUIDELINE; PROTEIN EXPRESSION; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; STANDARD;

EID: 84883038833     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2013.27     Document Type: Article

References (19)

1. Béné MC, Kaeda JS. How and why minimal residual disease studies are necessary in leukemia: A review from WP10 and WP12 of the European LeukaemiaNet. Haematologica 2009; 94: 1135-1150
2. San Miguel JF, Vidriales MB, Lopez-Berges C, az-Mediavilla J, Gutierrez N, Canizo C et al. Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. Blood 2001; 98: 1746-1751
3. San Miguel JF, Martínez A, Macedo A, Vidriales MB, Ló pez-Berges C, Gonzá lez M et al. Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients. Blood 1997; 90: 2465-2470 (Pubitemid 27392732)
4. Venditti A, Buccisano F, Del Poeta G, Maurillo L, Tamburini A, Cox C et al. Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia. Blood 2000; 96: 3948-3952
5. Feller N, van der Pol MA, van Stijn A, Weijers GW, Westra AH, Evertse BW et al. MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia. Leukemia 2004; 18: 1380-1390 (Pubitemid 39136748)
6. Kern W, Voskova D, Schoch C, Hiddemann W, Schnittger S, Haferlach T. Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia. Blood 2004; 104: 3078-3085 (Pubitemid 39517010)
7. Sievers EL, Lange BJ, Alonzo TA, Gerbing RB, Bernstein ID, Smith FO et al. Immunophenotypic evidence of leukemia after induction therapy predicts relapse: Results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia. Blood 2003; 101: 3398-3406 (Pubitemid 36857920)
8. Campana D, Coustan-Smith E. Detection of minimal residual disease in acute leukemia by flow cytometry. Cytometry 1999; 38: 139-152 (Pubitemid 29390417)
9. Langebrake C, Creutzig U, Dworzak M, Hrusak O, Mejstrikova E, Briesinger F et al. Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: The MRD-AML-BFM Study Group. J Clin Oncol 2006; 24: 3686-3692 (Pubitemid 46630545)
10. Buccisano F, Maurillo L, Del Principe MI, Del Poeta G, Sconocchia G, Lo-Coco F et al. Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. Blood 2012; 119: 332-341
11. van der Velden VH, van der Sluijs-Geling A, Gibson BE, te Marvelde JG, Hoogeveen PG, Hop WC et al. Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol. Leukemia 2010; 24: 1599-1606
12. Rubnitz JE, Inaba H, Dahl G, Ribeiro RC, Bowman WP, Taub J et al. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: Results of the AML02 multicentre trial. Lancet Oncol 2010; 11: 543-552
13. Voskova D, Schnittger S, Schoch C, Haferlach T, Kern W. Use of five-color staining improves the sensitivity of multiparameter flow cytometric assessment of minimal residual disease in patients with acute myeloid leukemia. Leuk Lymphoma 2007; 48: 80-88 (Pubitemid 46991456)
14. Al-Mawali A, Gillis D, Lewis I. The role of multiparameter flow cytometry for detection of minimal residual disease in acute myeloid leukemia. Am J Clin Pathol 2009; 131: 16-26
15. Macedo A, San Miguel JF, Vidriales MB, Ló pez-Berges MC, García-Marcos MA, Gonzalez M et al. Phenotypic changes in acute myeloid leukaemia: Implications in the detection of minimal residual disease. J Clin Pathol 1996; 49: 15-18 (Pubitemid 26034141)
16. Baer MR, Stewart CC, Dodge RK, Leget G, Sulé N, Mró zek K et al. High frequency of immunophenotype changes in acute myeloid leukemia at relapse: Implications for residual disease detection (Cancer and Leukemia Group B Study 8361). Blood 2001; 97: 3574-3580
17. Van Wering ER, van Lochem EG, Leenders M, van der Sluijs-Gelling AJ, Wind H, Gratama JW et al. Three-color flowcytometric analysis of mature and immature hematological malignancies. A guideline of the Dutch Foundation for Immunophenotyping of Hematological Malignancies (SIHON). Biol Regul Homeost Agents 2004; 18: 313-326 (Pubitemid 40723671)
18. Levering WH, Preijers FW, van Wieringen WN, Kraan J, van Beers WA, Sintnicolaas K et al. Flow cytometric CD34 stem cell enumeration: Lessons from nine years external quality assessment within the Benelux countries. Cytometry B Clin Cytom 2007; 72: 178-188 (Pubitemid 46676750)
19. Feller N, Schuurhuis GJ, van der Pol MA, Westra G, Weijers GW, van Stijn A et al. High percentage of CD34-positive cells in autologous AML peripheral blood stem cell products reflects inadequate in vivo purging and low chemotherapeutic toxicity in a subgroup of patients with poor clinical outcome. Leukemia 2003; 17: 68-75 (Pubitemid 36175890)